IMMUNOCORE HOLDINGS PLC · Data as of 2026-09-08
H2 2026
The Company plans to file a CTA or investigational new drug (IND) application in the second half of 2026 for its second autoimmune program, IMC-U120AI (CD1a x PD1), which is designed to target a variety of dermatological diseases including atopic dermatitis.Source filing
Late 2026
The trial is event driven and topline data could come as early as the end of 2026.Source filing
Early 2027
Analysis of the new data is ongoing with results planned to be shared early next year.Source filing
2027
The Company expects to present initial data in 2027.Source filing
H2 2026
The Company expects to present Phase 1/2 data from both trials in the second half of 2026.Source filing
H2 2026
The Company expects to present Phase 1/2 data from both trials in the second half of 2026.Source filing